Robert Lai

JPMorgan Chase & Co (United States) — United States

Medicine · Health Sciences

27h-index3.6kcitations86works0.62yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Alzheimer's disease research and treatments(29), Cholinesterase and Neurodegenerative Diseases(12), Dementia and Cognitive Impairment Research(11), Computational Drug Discovery Methods(9), Statistical Methods in Clinical Trials(7)

Publications86 total

Calycosin improves insulin resistance by regulating the hsa-miR-324-3p/AKT pathway to inhibit FOXO3a nuclear transfer
Xenobiotica·2025
Decrypting the complex neuroimmune interactions underlying brain injury during cryptococcal infection
Neuroscience·2025
Independent and joint association of accelerometer-measured sedentary behaviour and physical activity with mild cognitive impairment and intrinsic capacity decline among Chinese older adults: study protocol for a cross-sectional study
BMJ Open·2025· 2 citedOpen Access
Quantum-safe MACsec Connectivity to Public Cloud Providers in a Metropolitan Network over Deployed Fiber
2025· 1 cited
PROGRESS‐AD: a phase 2 study to evaluate efficacy and safety of GSK4527226 (AL101), an anti‐sortilin monoclonal antibody, in patients with early Alzheimer’s disease
Alzheimer s & Dementia·2024Open Access
Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027
Alzheimer Disease & Associated Disorders·2022· 10 cited
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Alzheimer s Research & Therapy·2022· 17 citedOpen Access
E2027 Cardiac Safety Evaluation With Concentration-Response Modeling of ECG Data to Inform Dose Selection in Studies in Patients With Dementia With Lewy Bodies
Alzheimer Disease & Associated Disorders·2022· 1 cited
Lecanemab, an anti-Aβ protofibril antibody: Updated data from a randomized, double-blind phase 2B proof of concept clinical trial and open-label extension in early Alzheimer's disease
Journal of the Neurological Sciences·2021· 3 cited
Lewy Body Dementia Association’s Industry Advisory Council: proceedings of the second annual meeting
Alzheimer s Research & Therapy·2021· 1 citedOpen Access
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Alzheimer s Research & Therapy·2021· 759 citedOpen Access
Preliminary Analysis Of BAN2401 Effects On Brain Amyloid And ARIA-E Findings Over 12 Months Of Treatment In The Open-Label Extension Of The Phase2b Study BAN2401-G000-201 In Subjects With Early Alzheimer’s Disease (3006)
Neurology·2021
A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer’s disease
Alzheimer s & Dementia·2020· 1 citedOpen Access
A preliminary account of ARIA‐E in the ongoing open‐label extension phase of BAN2401‐G000‐201 in subjects with early Alzheimer’s disease
Alzheimer s & Dementia·2020Open Access
Persistence Of BAN2401-Mediated Amyloid Reductions Post-treatment: A Preliminary Comparison of Amyloid Status Between the Core Phase of BAN2401-G000-201 and Baseline of the Open-Label Extension Phase in Subjects with Early Alzheimer’s Disease (1330)
Neurology·2020· 10 cited
A Randomized, Double-Blind Phase 2b Proof of Concept Clinical Trial in Early Alzheimer's Disease with BAN2401, an Anti-Aβ Protofibril Antibody
SSRN Electronic Journal·2020Open Access
P4‐657: POPULATION PHARMACOKINETIC/PHARMACODYNAMIC ANALYSES OF BAN2401 IN PATIENTS WITH EARLY ALZHEIMER'S DISEASE: CORRELATION OF BAN2401 EXPOSURE, PET STANDARD UPTAKE VALUE RATIO, AND COGNITIVE OUTCOMES
Alzheimer s & Dementia·2019· 4 cited
DT‐01‐01: BAN2401 IN EARLY ALZHEIMER'S DISEASE: NEURODEGENERATION BIOMARKER ANALYSIS FROM A RANDOMIZED PHASE 2 STUDY
Alzheimer s & Dementia·2019· 3 citedOpen Access
P1‐040: ELENBECESTAT, A NOVEL BACE INHIBITOR, DEMONSTRATES SIMILAR PHARMACOKINETICS AND TOLERABILITY IN JAPANESE SUBJECTS WITH MULTIPLE DOSINGS
Alzheimer s & Dementia·2018· 2 cited
P1‐055: E2027, A NOVEL PHOSPHODIESTERASE‐9 (PDE9) INHIBITOR IN DEVELOPMENT FOR TREATMENT OF DEMENTIA WITH LEWY BODIES (DLB), SHOWED NO CLINICALLY SIGNIFICANT DRUG INTERACTION WITH DILTIAZEM
Alzheimer s & Dementia·2018· 1 cited
page 1 of 5Next →

Frequent Co-authors

June Kaplow(11), Chad J. Swanson(10), Neil Upton(10), Shobha Dhadda(6), Lars Lannfelt(6), Lynn D. Kramer(6), Claude M. Wischik(6), Charles R. Harrington(6), Martin Rabe(5), Larisa Reyderman(5), Robert J. Gordon(5), Andrew Satlin(5), Vincent J. Cunningham(5), Eugenii A. Rabiner(5), Heather Bradley(4), Akihiko Koyama(4), Patricia C. Edwards(4), Martin Roth(4), Jonathan Bullman(4), Nick Bird(4)